37 completed, 8 terminated, 4 unknown, 1 active not recruiting. 27 Phase 1, 18 Phase 2, 8 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Stage III Grade 3 Follicular Lymphoma: new trials by email Literature Review of Stage III Grade 3 Follicular Lymphoma trials Research Report on Stage III Grade 3 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 anti-CD19-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Unknown | Chinese PLA General Hospital | 12 | 2013-04-01 | 2016-01-28 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma bortezomib, filgrastim, autologous hematopoietic stem cell transplantation - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 23 | 2011-07-01 | 2021-05-10 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer palifermin, flow cytometry, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Martin, Paul | 6 | 2010-09-01 | 2014-04-02 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies plerixafor, filgrastim, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Terminated | Fred Hutchinson Cancer Center | 1 | 2010-06-01 | 2017-06-28 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy CART-19 - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | University of Pennsylvania | 26 | 2010-03-17 | 2023-06-22 |
Showing 20 of 51. Sign in to see all of them.
Lymphoma, Follicular (51) · Leukemia, Lymphocytic, Chronic, B-Cell (50) · Lymphoma, Large B-Cell, Diffuse (48) · Lymphoma, Mantle-Cell (48) · Lymphoma, B-Cell, Marginal Zone (43) · Lymphoma, Non-Hodgkin (41) · Burkitt Lymphoma (40) · Lymphoma, Large-Cell, Immunoblastic (39) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Hodgkin Disease (33) · Lymphoma, T-Cell, Cutaneous (31) · Mycosis Fungoides (30) · Sezary Syndrome (30) · Waldenstrom Macroglobulinemia (29) · Lymphoma, Large-Cell, Anaplastic (24)
Hemic and Lymphatic Diseases (51) · Immune System Diseases (51) · Immunoproliferative Disorders (51) · Lymphatic Diseases (51) · Lymphoproliferative Disorders (51) · Neoplasms (51) · Neoplasms by Histologic Type (51) · Chronic Disease (50) · Disease Attributes (50) · Hematologic Diseases (50) · Leukemia, B-Cell (50) · Leukemia, Lymphoid (50) · Lymphoma (50) · Pathologic Processes (50) · Pathological Conditions, Signs and Symptoms (50)
Rituximab (9) · fludarabine phosphate (9) · Cyclophosphamide (8) · Mycophenolic Acid (7) · Peripheral Blood Stem Cell Transplantation (7) · Whole-Body Irradiation (7) · Tacrolimus (6) · Cyclosporine (4) · Flow Cytometry (4) · Therapeutics (4) · Bortezomib (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Polymerase Chain Reaction (3) · Vorinostat (3)
National Cancer Institute (NCI) (19) · Fred Hutchinson Cancer Center (10) · Chinese PLA General Hospital (4) · City of Hope Medical Center (3) · Roswell Park Cancer Institute (3) · Case Comprehensive Cancer Center (2) · Amir Mortazavi (1) · Barbara Ann Karmanos Cancer Institute (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Martin, Paul (1) · Northwestern University (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1) · University of Chicago (1) · University of Nebraska (1) · University of Pennsylvania (1)
United States (44) · China (5) · Canada (2) · Germany (2) · Italy (2) · Denmark (1)
Paul Martin (3) · Brenda Sandmaier (2) · Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Amir Mortazavi, MD (1) · Ann Woolfrey (1) · Antonius Miller (1) · Barbara Grant (1) · Brian Hill, MD (1) · Chandra Belani (1) · Charles Erlichman (1) · Colleen Delaney (1) · David Maloney (1) · Divaya Bhutani, M.D. (1) · Francisco Hernandez-ILizaliturri (1)
PMID 32499241, PMID 34515338, PMID 18698002, PMID 25085357, PMID 25317870, PMID 25444722, PMID 26451310, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28817727, PMID 29263894, PMID 29599530, PMID 30562587, PMID 31076448, PMID 31388792, PMID 31815579, PMID 32245502, PMID 32628342, PMID 33420905, PMID 33492438, PMID 36282798, PMID 40720747, PMID 41804087
P30CA015704 (4), P01CA018029 (3), U01CA062491 (3), P30CA022453 (2), U01CA062487 (2), U01CA069912 (2), U01CA076576 (2), U01CA099168 (2), U01CA132123 (2), U10CA031946 (2), N01CM62208 (1), P01CA078902 (1), P30CA014520 (1), P30CA014599 (1), P30CA015083 (1)